Pentixapharm Signs Manufacturing Deal with Eckert & Ziegler for Clinical Trial Supply

• Pentixapharm has signed a clinical-stage manufacturing agreement with Eckert & Ziegler Radiopharma GmbH for its radiotherapeutic candidate Y90-PentixaTher.

• EZR will manufacture and distribute patient-specific GMP doses of the drug for ongoing clinical trials.

Pentixapharm, a clinical-stage biopharmaceutical company, has announced a manufacturing agreement with Eckert & Ziegler Radiopharma GmbH (EZR), a subsidiary of Eckert & Ziegler SE. Under the deal, EZR will produce patient-specific doses of Y90-PentixaTher, Pentixapharm’s CXCR4-targeting radiotherapeutic, for use in clinical trials.

The agreement involves the GMP manufacturing and direct shipment of Y90-PentixaTher doses to participating trial sites. The arrangement is specific to the clinical development phase and does not include commercial-scale production. Pentixapharm retains full control over its future supply strategy beyond the current clinical stage.

Y90-PentixaTher is a radiolabeled peptide designed to selectively irradiate cancer cells that overexpress the CXCR4 receptor, which is prevalent in various haematological cancers and solid tumours. It uses Yttrium-90, chosen for its deeper tissue penetration and shorter half-life compared to alternatives such as Lutetium-177. When combined with the diagnostic agent Ga68-PentixaFor, the treatment supports a theranostic approach, enabling both imaging and therapy.

Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE, commented: “Reliable access to high-quality radioisotopes is critical for the development of next-generation radiopharmaceuticals and we are pleased to contribute our manufacturing excellence to accelerate the delivery of innovative cancer therapies.”

Dr. Dirk Pleimes, CEO of Pentixapharm AG, said the deal was “a significant milestone” in advancing their targeted radiopharmaceutical programme towards late-stage development.